On April 14, 2025, Soligenix, Inc. (SNGX) announced interim results from the ongoing, open label, investigator initiated study (IIS) evaluating HyBryte (synthetic hypericin) treatment for up to 54 weeks in patients with early stage cutaneous T cell lymphoma (CTCL). Of the eight evaluable patients at Week 18, six (75%) achieved 'treatment success', which is defined as a =50% improvement in the cumulative mCAILS (modified Composite Assessment of Index Lesion Severity) score compared to baseline. Four patients have completed the 54-week treatment with an average maximum improvement in mCAILS of 85%. Lastly, three patients have achieved a complete response. We anticipate additional study updates as the data become available.
